Growth • AstraZeneca
AZN
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
17,3%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
27,9%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
39,4%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
34,3%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
33,7%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
31,9%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!